TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Nov 29, 2022 19:28 JST
Source:
Eisai
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
TOKYO, Nov 29, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today. (Please refer to "Notes to Editors" on the link below for details of the changes)
This partial change to label is based on the results of a reexamination for the indication of "suppression of progression of dementia symptoms in dementia with Lewy bodies" of this drug, which was categorized as Category 2.
After receiving approval for the partial change in dosage and administration for DLB, Eisai will continue to place the highest priority on the provision of proper use and safety information for this drug, and will make continued contributions to address the diversified needs of, and increase the benefits provided to people living with DLB and their families.
For more information visit www.eisai.com/news/2022/news202282.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
More Press release >>
Latest Press Release
Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025
Oct 30, 2025 00:26 JST
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
Oct 30, 2025 00:18 JST
Overview of Honda CEO Speech at the Japan Mobility Show 2025
Oct 30, 2025 00:00 JST
Honda Presents World Premiere of the Prototype of Honda 0 a, new SUV Model for Honda 0 Series at Japan Mobility Show 2025
Oct 29, 2025 23:55 JST
Honda Presents World Premiere of Super-ONE Prototype Compact EV at Japan Mobility Show 2025
Oct 29, 2025 23:50 JST
Mitsubishi Motors Debuts Mitsubishi Elevance Concept and Adventure-Inspiring Lineup at Japan Mobility Show 2025
Oct 29, 2025 23:39 JST
Fujitsu and PwC Japan partner on economic security measures for sovereign cloud solution
Oct 29, 2025 23:22 JST
Hitachi Rail becomes world's first transportation firm to adopt new NVIDIA IGX Thor solution for real-time AI
Oct 29, 2025 23:00 JST
Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center
Oct 29, 2025 11:00 JST
Gannon & Scott has signed a definitive agreement to join Metalor Technologies
Oct 29, 2025 04:00 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Oct 29, 2025 00:30 JST
Mitsubishi Heavy Industries Machinery Systems to Exhibit at Japan Mobility Show 2025
Oct 29, 2025 00:00 JST
Fujitsu AI transforms regional healthcare in Iki city
Oct 28, 2025 23:24 JST
Hitachi announces initiatives aligned with Japan - U.S. strategic investments
Oct 28, 2025 22:34 JST
NEC Achieves Cisco Gold Provider Status, Strengthening Global Strategic Partnership in the AI era
Oct 28, 2025 22:09 JST
Honda to Invest in OMC Power, which will Launch Leasing Business for Uninterruptible Power Supply Device in India
Oct 27, 2025 21:20 JST
Fujitsu, Logistics Knight Japan, and Isuzu Motors launch joint pilot project to build pharmaceutical logistics platform aiming for stable supply
Oct 27, 2025 17:31 JST
JCB Explores Opportunities to Expand Card Acceptance through Partnership with STC Bank
Oct 27, 2025 15:00 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
Oct 27, 2025 14:23 JST
FIG, Fujitsu, Acer Medical collaborate to develop health-promoting insurance concept to support preventative care in aging societies
Oct 24, 2025 16:52 JST
More Latest Release >>